Compare EPR Properties (EPR) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs Inovio Pharmaceuticals Inc — how do they compare? EPR Properties trades at $61.2 (market cap $4.58B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: EPR Properties is far larger — about 58.3× Inovio Pharmaceuticals Inc's market cap, and EPR Properties pays a 6.22% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| EPR | INO | |
|---|---|---|
Market Cap | $4.58B | $78.55M |
Sector | Real Estate | Health |
52-Week High | $64.32 | $2.87 |
52-Week Low | $48.71 | $0.66 |
Enterprise Value | $8.09B | $49.56M |
Dividend Yield | 6.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties (EPR) trades at $61.41, up 1.67% in the last session, with a bearish technical signal despite strong Q2 2026 FFO beating estimates. The company reported revenue growth to $699 million in 2026, though net income dipped to $263 million, and maintains a high gross margin of 91.41%. Recent news highlights dividend declarations and a new $1.6 billion credit facility, supporting its experiential real estate focus.
Outlook is mixed: analyst consensus favors 'Hold' with a $65.30 price target, indicating modest upside, but technical indicators and a slight earnings miss in Q1 2026 pose risks. Opportunities include dividend growth and portfolio diversification, while risks involve investing cash flow volatility and sector competition.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
